
Granules India Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Finished Dosage (FD) segment will be the main driver of future growth with healthy, possibly better than last year's growth.
- New product launches, including CNS, ADHD, MUPS, and first-to-file launches, will significantly contribute to revenue growth starting FY25 and more markedly in FY26.
- Value-added products expected to increase from 65% to around 70% of sales by next year, enhancing margins and revenue quality.
- Formulation capacity ramp-up at Genome Valley expected to touch annualized revenue capacity of INR 4-5 billion by FY25.
- New products anticipated to contribute 7-10% to FY25 revenues, with growth accelerating in subsequent years.
- Market expansion, including increasing presence in U.S., Europe, and other regulated markets, supports volume and sales growth.
- Despite challenges in Paracetamol API segment, stabilization expected from FY26 and overall good demand environment for most products.
See what Granules India management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no indication of any new fundraising through debt or equity in the call.
- The company plans capex of around INR 600 crores for FY25, primarily for Granules Life Sciences expansion and other projects.
- Net debt as of year-end is INR 842 crores, with a targeted net debt-to-EBITDA ratio of around 1 to 1.1, which the company aims to maintain rather than drastically reduce.
- No plans to bring net debt down drastically; small fluctuations plus or minus may occur.
- The company intends to maintain healthy net debt levels and is cautious about taking on more debt to keep the ratio within target.
- Interest costs are expected to remain steady in the near term due to Fed rates.
- Overall, no new fundraising announcements or plans were shared in the discussion.
See what Granules India management said on order book — free account, 30 seconds.
Capex plans
Yes- FY25 Capex estimated at INR 600 crores (INR 6,000 million).
- Half of the capex allocated to Granules Life Sciences expansion; remaining for other projects and maintenance.
- New formulation facility at Genome Valley (Granules Life Sciences) commenced operations in March 2024 with ramp-up expected to reach 100 million dosages per month by July-August 2024.
- Granules Life Sciences capacity expected to generate INR 4-5 billion revenue in FY25.
- Cautious approach to CZRO investment; spending aligned with project milestones ("state gate" approvals).
- Commercial scale-up planned for the DCDA pilot plant at Kakinada following successful pilot operations in March 2024.
- Strategic capex focused on backward integration of paracetamol and metformin in a sustainable manner (green pharma initiative).
- Emphasis on expanding manufacturing technology platform and validation of new molecules by Q3 FY25 to achieve cost leadership and sustainability.
Track Granules India — get its next earnings analysis in your feed
How does Granules India rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Granules India rank in Pharmaceuticals & Biotechnology?
Compare Granules India against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Granules India's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem